Autoimmune Hemolytic Anemia Associated With Ulcerative Colitis: The Most Important Step Is to Induce Complete Remission

2010 ◽  
Vol 105 (5) ◽  
pp. 1203-1204 ◽  
Author(s):  
Tamás Molnár ◽  
Klaudia Farkas ◽  
Zoltán Szepes ◽  
Ferenc Nagy ◽  
Tibor Wittmann
Keyword(s):  
Ulcerative Colitis ◽  
Complete Remission ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia in ulcerative colitis

1979 ◽  
Vol 24 (4) ◽  
pp. 282-285 ◽  
Author(s):  
Alan R. Altman ◽  
Charles Maltz ◽  
Henry D. Janowitz
Keyword(s):  
Ulcerative Colitis ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia Associated With Ulcerative Colitis: Response to Infliximab

2009 ◽  
Vol 104 (9) ◽  
pp. 2370-2371 ◽  
Author(s):  
Eduardo Leo Carnerero ◽  
Sami Aoufi ◽  
Isabel Montero Cuadrado ◽  
Pablo Herrera Martin ◽  
Jose Manuel Herrera Justiniano
Keyword(s):  
Ulcerative Colitis ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia

scholarly journals Autoimmune Cytopenias and Covid-19 Vaccination: Relapse and Suggested Treatment

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4141-4141
Author(s):  
Gregorio Campos-Cabrera ◽  
Francisco-Gerardo Torres-Salgado ◽  
Salvador Campos-Cabrera ◽  
Jose-Luis Campos-Villagomez ◽  
Virginia Campos-Cabrera
Keyword(s):  
Complete Remission ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
De Novo ◽  
Conflicts Of Interest ◽  
High Dose ◽  
Evans Syndrome ◽  
Autoimmune Thrombocytopenia ◽  
Platelet Counts ◽  
Autoimmune Cytopenias

Abstract Introduction: There are "de novo" and relapsed autoimmune diseases in patients with COVID-19 that includes autoimmune thrombocytopenia, Evans syndrome and autoimmune hemolytic anemia among others (Hematology 2021;26:225-239 and Curr Rheumatol Rev 2021;17:193-204). There is scanty material about relapse of autoimmune hematological diseases after vaccination for COVID-19 (Blood Adv 2021;13:2794-2798). Material and methods: Adult patients 18 years or older with autoimmune thrombocytopenia, Evans syndrome and autoimmune hemolytic anemia who completed SARS-Cov2 vaccination. Results: Between December 2020 and June 2021 there were identified 53 patients with autoimmune hematological disease that completed SARS-Cov2 vaccination. Thirty-six with autoimmune thrombocytopenia, all were preexisting. Twelve with autoimmune hemolytic anemia, 5 secondaries to previous COVID-19 and 7 preexisting. Five with Evans syndrome, all preexisting. Twenty-three patients with autoimmune thrombocytopenia did not develop any fall in the platelet count. Ten patients had a fall of 50 % from basal counts and recovered spontaneously. Three patients developed counts below 30,000 with purpuric symptoms and needed treatment that consisted in two courses of dexamethasone 40 mg daily for four days every three weeks; all patients reached complete remission without any further treatment. All patients with Evans syndrome developed hemolysis and low platelet counts. Two patients maintained Hb levels above 10 and platelet counts above 50,000; both patients had spontaneously recovery. Three patients developed Hb levels below 7 with anemic syndrome and platelets below 50,000 but without purpuric syndrome; they received the same treatment as patients with autoimmune thrombocytopenia and reached complete remission too. All five patients with autoimmune hemolytic anemia secondary to COVID-19 developed Hb levels below 7 with anemic symptoms and needed treatment as described. The remaining 7 patients with preexisting autoimmune anemia developed hemolysis; five with Hb levels above 7 and recovery without any treatment; two had Hb levels below 7 and received the same treatment with full recovery and complete remission. Conclusions: Autoimmune cytopenias can be trigger by vaccines and viral infections by involving molecular mimicry and circulating immune complexes, including SARS-Cov2. The viral protein spike from SARS-Cov2 has mimicry between the Ankyrin-1 in the erythrocyte surface, and has been linked as one of the pathogenesis pathways of autoimmune hemolytic anemia secondary to COVID-19 (Br J Haematol 2020;190:e92-e93 and Blood 2020;136:suppl8,138001). Relapse of autoimmune cytopenias after vaccination with SARS-Cov2 involves stimulation of autoantibodies production from preexisting B cells. Although relapses were observed in the three kinds of patients, all with hemolytic component developed a drop in the hemoglobin levels, most of them needed treatment. It is important to notice that patients with hemolytic autoimmune anemia secondary COVID-19 had severe relapse, event that support the mimicry mentioned lines above. It is important to follow up closely this kind of patients after SARS-CoV2 vaccination, we suggest weekly complete blood counts, and a short courses of high dose dexamethasone can induce curable responses if treatment is advised. Disclosures No relevant conflicts of interest to declare.

Ulcerative Colitis Complicated by Autoimmune Hemolytic Anemia

1981 ◽  
Vol 74 (3) ◽  
pp. 359-361 ◽  
Author(s):  
DANIEL W. BELL ◽  
ERNEST URBAN ◽  
DAVID A. SEARS ◽  
ARNOLD I. WALDER ◽  
VICTOR S. OSTROWER
Keyword(s):  
Ulcerative Colitis ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia

AUTOIMMUNE HEMOLYTIC ANEMIA IN ULCERATIVE COLITIS, CURED BY COLECTOMY

2009 ◽  
Vol 189 (1-6) ◽  
pp. 275-277 ◽  
Author(s):  
O. Arner ◽  
J. Brohult ◽  
L. Engstedt ◽  
R. Karlson ◽  
T. Sällström
Keyword(s):  
Ulcerative Colitis ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia in Ulcerative Colitis A Case Report with Review of the Literature

1991 ◽  
Vol 13 (4) ◽  
pp. 445-447 ◽  
Author(s):  
F. Tavarela Veloso ◽  
J. Fraga ◽  
J. Carvalho ◽  
L. M. Dias ◽  
M. Ceu Salgado
Keyword(s):  
Ulcerative Colitis ◽  
Case Report ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Review Of The Literature

High-dose cyclophosphamide for refractory autoimmune hemolytic anemia

Blood ◽  
2002 ◽  
Vol 100 (2) ◽  
pp. 704-706 ◽  
Author(s):  
Victor M. Moyo ◽  
Douglas Smith ◽  
Isadore Brodsky ◽  
Pamela Crilley ◽  
Richard J. Jones ◽  
...  
Keyword(s):  
Stem Cell ◽  
Complete Remission ◽  
Hemolytic Anemia ◽  
Absolute Neutrophil Count ◽  
Autoimmune Hemolytic Anemia ◽  
High Dose ◽  
Safety And Efficacy ◽  
Stem Cell Rescue ◽  
Age And Sex

Abstract High-dose cyclophosphamide, without stem cell rescue, has been used successfully to treat aplastic anemia and other autoimmune disorders. To determine the safety and efficacy of high-dose cyclophosphamide among patients with severe refractory autoimmune hemolytic anemia, we treated 9 patients with cyclophosphamide (50 mg  ·  kg−1  ·  d−1 for 4 days) who had failed a median of 3 (range, 1-7) other treatments. The median hemoglobin before treatment was 6.7 g/dL (range, 5-10 g/dL). The median time to reach an absolute neutrophil count of 500/μL or greater was 16 days (range, 12-18 days). Six patients achieved complete remission (normal untransfused hemoglobin for age and sex), and none have relapsed after a median follow-up of 15 months (range, 4-29 months). Three patients achieved and continue in partial remission (hemoglobin at least 10 g/dL without transfusion support). High-dose cyclophosphamide was well tolerated and induced durable remissions in patients with severe refractory autoimmune hemolytic anemia.

Sign in / Sign up

Export Citation Format

Share Document